Navigation Links
Vanda Pharmaceuticals Submits Iloperidone New Drug Application
Date:9/27/2007

ROCKVILLE, Md., Sept. 27 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia. The application includes data from 35 clinical trials and more than 3,000 patients treated with iloperidone.

Iloperidone has demonstrated efficacy in treating the symptoms of schizophrenia both in the acute and the chronic setting. Iloperidone's binding to a number of dopamine and serotonin receptors provides a favorable safety profile on adverse symptoms, such as weight gain, extrapyramidal symptoms, akathisia and prolactin elevation. The NDA submission also contains pharmacogenetic data aimed to further improve the benefit/risk profile of iloperidone in the treatment of patients with schizophrenia.

"The submission of the iloperidone NDA marks a significant milestone for Vanda. Iloperidone may become an important instrument in the treatment of patients with schizophrenia and may help to usher the field of psychiatry into an era of personalized medicine," said Mihael H. Polymeropoulos, M.D., President and CEO, Vanda Pharmaceuticals Inc.

"For a serious brain disorder like schizophrenia, which affects about three million Americans in the prime of life, it is vital that new pharmacotherapeutic agents be developed in light of the fact that existing antipsychotic treatments work partially in some patients and not others, leaving many patients continuously disabled. The NIMH-funded CATIE effectiveness study revealed the efficacy or safety limitations of current agents. Iloperidone is a new antipsychotic that c
'/>"/>

SOURCE Vanda Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the Annual Meeting of the Associated Professional Sleep Societies
2. Vanda Pharmaceuticals to Present Data on Iloperidone at the 2007 American Psychiatric Association Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... LONDON , March 26, 2015 ... release, please scroll to bottom . Investor-Edge ... (NASDAQ: MYL ), Salix Pharmaceuticals Ltd (NASDAQ: ... Inc. (NASDAQ: VVUS ), and Akorn Inc. (NASDAQ: ... be accessed at http://get.Investor-Edge.com/pdf/?c=Mylan&d=26-Mar-2015&s=MYL . The US markets ...
(Date:3/26/2015)... , Kalifornien, 26. März 2015 ... 2015, die sich speziell an Innovatoren, Visionäre ... Die zweitägige Konferenz für geladene ... 2015 im Hyatt Regency in ... diesem Forum werden führende Akteure der Biowissenschaften ...
(Date:3/26/2015)... de março de 2015 A Finesse Solutions ... projetado especificamente para os inovadores, visionários e executivos seniores ... apenas por convite, será realizada no Hyatt Regency em ... e 22 de setembro de 2015. Será um fórum ... futuro da fabricação de produtos biofarmacêuticos de uso único ...
Breaking Medicine Technology:Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 2Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 3Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 4Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 5Finesse Solutions kündigt Cellworld 2015 an 2Finesse Solutions anuncia Cellworld 2015 2
... For the second year in a row the New York Yankees ... Hearing Foundation deliver the gift of hearing to more than ... The Starkey Hearing Foundation New York Yankees Hearing Mission was held ... New York Yankees Pitcher CC Sabathia, Manager Joe Girardi and ...
... 2011 In strong collaboration with clinical research partners, ... of the LokomatPro that offers greater system capabilities. Since ... 2001, the LokomatPro has established itself as an effective ... neurological diseases and injuries resulting in gait impairment. ...
Cached Medicine Technology:New York Yankees Help Starkey Hearing Foundation Deliver the Gift of Hearing to New York Area Children and Adults in Need 2New York Yankees Help Starkey Hearing Foundation Deliver the Gift of Hearing to New York Area Children and Adults in Need 3Hocoma Launches New Version of its Established Gait Training Device LokomatPro 2
(Date:3/26/2015)... York (PRWEB) March 26, 2015 ... move forward nationwide, with the issuance of new ... Pennsylvania and Louisiana. According to an Order dated ... litigation established for Xarelto injury claims in the ... now allow plaintiffs to file cases directly in ...
(Date:3/26/2015)... “The SWEET Act is an important step to invigorate ... help parents who are working to reduce sugar in their ... support public health, and we will continue to stand on ... all families,” said Dr. Jane Delgado President and CEO of ... the Sugar-Sweetened Beverage Tax (SWEET) Act by Congresswoman Rosa L. ...
(Date:3/26/2015)... March 26, 2015 Dr. Alex Rabinovich ... to announce expanded offerings for Bay Area patients considering ... Implant Center has long been a top-rated center, serving ... offerings to meet the strong demand by others throughout ... as a top-rated dental implant facility in San Francisco,”explained ...
(Date:3/26/2015)... Springs, FL (PRWEB) March 26, 2015 ... of the nation’s leading innovative specialty pharmacies, announces ... created position of Vice President of Pharmaceutical Relations. ... fostering beneficial connections with our pharmaceuticals partners and ... relationships in support of BioPlus’ expansion. , ...
(Date:3/26/2015)... UK (PRWEB) March 26, 2015 In the ... billion as of 2013 and is set to decrease through ... by 2020; the growth is expected up to 2017 at ... is expected to be owing to the surging penetration of ... HCT, Twynsta, Micardis Plus, Valturna, Benicar HCT, and Tekamlo), a ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 2Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 3Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act in 114th Congress 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3Health News:BioPlus Specialty Pharmacy Expands Executive Team with New Position, Naming Sharon Ferrer as Vice President of Pharmaceutical Relations 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3
... , ... Disease Foundation (VDF) is seeking nominations for the 2010 President’s Awards, which recognize those ... disease or have assisted the Foundation in accomplishing its mission in various categories. The ... ...
... ... this health observance day, VIP Smiles, owned by celebrity dentist Dr. Catrise Austin ... Street location by appointment from June 21st - June 28th, 2010. VIP Smiles ... offer the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test, which can be administered orally ...
... By combining two relatively inexpensive technologies based on sound and ... women undergo breast biopsies for suspicious lesions. Results of the ... edition and the August print issue of Radiology . ... the potential of diffuse optical tomography in the near infrared ...
... realize international health goals aiming to improve maternal health, ... is crucial. In an editorial published this week entitled ... editors argue that action on maternal health must ... much as it does access to basic medical care. ...
... appendages such as hair, nails, sweat glands and mammary ... the United States, according to a report in the ... of the JAMA/Archives journals. "Cutaneous appendageal carcinomas are ... diverse differentiation that frequently present a diagnostic challenge," the ...
... A new study in the journal Respirology ... acute exacerbations of chronic obstructive pulmonary disease (COPD) experience ... an increased risk of death, compared to those without ... due to impairment of immune responses. Researchers led by ...
Cached Medicine News:Health News:Nominations Wanted for Vascular Disease Foundation President's Awards 2Health News:June 27th Is National HIV Testing Day-New York Celebrity Dentist Offers Free Oral Rapid HIV Testing In the Dental Office 2Health News:June 27th Is National HIV Testing Day-New York Celebrity Dentist Offers Free Oral Rapid HIV Testing In the Dental Office 3Health News:Noninvasive combination technique may reduce number of breast biopsies 2Health News:Cancers of sweat glands, other skin-related structures may be increasing in United States 2
... Mosaic, the third generation tissue valve ... stented tissue valve available. The Mosaic valve ... experience and is an excellent choice for ... replacement with a tissue valve. For more ...
... bioprosthesis from Medtronic has more ... clinical experience. Worldwide clinical studies ... structural valve deterioration with Hancock® ... is substantially better than results ...
... The Hancock® II bioprosthesis ... 15 years of proven clinical ... that the freedom from structural ... aortic and mitral bioprostheses is ...
Attain Venogram Balloon Catheter....
Medicine Products: